Phenytoin toxicity management
Reading File
Finding Sources
Finding Sources
Searching PubMed
phenytoin toxicity management
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Here is a structured overview of phenytoin toxicity management:
Phenytoin Toxicity — Management
Pharmacology Background
Phenytoin blocks voltage-sensitive, frequency-dependent sodium channels, suppressing repetitive neuronal activity. It is available orally and as an IV formulation — the parenteral vehicle contains 40% propylene glycol + 10% ethanol at pH 12, which is responsible for most cardiovascular toxicity seen with IV use.
Fosphenytoin is a prodrug (converted by phosphatases in ~10–15 min) that avoids the propylene glycol vehicle, is water-soluble, and can be given IM — but cardiovascular toxicity can still occur.
Clinical Features of Toxicity
CNS (most common, dose-related)
| Plasma Level (µg/mL) | Toxic Effects |
|---|---|
| < 10 | Usually none |
| 10–20 | Occasional mild nystagmus |
| 20–30 | Nystagmus |
| 30–40 | Ataxia, slurred speech, nausea/vomiting |
| 40–50 | Lethargy, confusion |
| > 50 | Coma, seizures |
Nystagmus is the earliest sign — first on forced lateral gaze, then spontaneous. Progression: sedation → lethargy → ataxia → dysarthria → confusion → coma → apnea.
Additional CNS: tremor, diplopia, ophthalmoplegia, choreoathetoid movements, hallucinations, encephalopathy.
Cardiovascular (IV administration only)
Cardiac toxicity after isolated oral overdose in a healthy patient has not been reported. IV toxicity is primarily due to the propylene glycol diluent:
- Hypotension (decreased peripheral vascular resistance)
- Bradycardia, AV nodal block (can progress to complete block)
- Ventricular tachycardia, ventricular fibrillation, asystole
- ECG changes: ↑PR interval, widened QRS, ST/T changes
- Higher risk in elderly, underlying cardiac disease, critically ill
Vascular/Soft Tissue (IV extravasation)
- Skin and soft tissue necrosis
- Compartment syndrome, limb gangrene
- "Purple glove syndrome": delayed bluish discoloration → erythema → edema → vesicles/bullae → tissue ischemia
Hypersensitivity (onset 1–6 weeks after starting therapy)
- Anticonvulsant hypersensitivity syndrome: eosinophilia, rash, pseudolymphoma, SLE, pancytopenia, hepatitis, pneumonitis
Other chronic toxicities
- Gingival hyperplasia, hirsutism, acne, coarsening of facial features
- Fetal hydantoin syndrome, hemorrhagic disease of newborn
- Stevens-Johnson syndrome
- Peripheral neuropathy, hyperglycemia/hypoglycemia
Diagnosis
- Therapeutic range: total phenytoin 10–20 µg/mL (40–80 µmol/L); free phenytoin 1–2 µg/mL
- Oral absorption is slow, variable, and erratic — peak typically 3–12 hours after a single dose; delayed further in overdose
- Serial levels are required — a single level cannot determine peak or guide discharge
- Hypoalbuminemia alters interpretation (phenytoin is ~90% protein-bound); use the Sheiner-Tozer correction or measure free phenytoin directly in patients with hypoalbuminemia or renal failure
Treatment
General (oral overdose)
- Airway, breathing, circulation — standard supportive care
- Correct acidosis (respiratory or metabolic) — acidosis increases the free (active) fraction of phenytoin
- Activated charcoal: Multidose activated charcoal (MDAC) may decrease drug half-life but does not decrease time to recovery or change outcome — consider if not obtunded and within a reasonable window
- Cardiac monitoring: Not necessary after isolated oral ingestion
- Seizures: Treat with IV benzodiazepines or phenobarbital (note: seizures are uncommon in phenytoin overdose)
- Severe/persistent toxicity: Hemodialysis and hemoperfusion can produce substantial improvement in neurologic toxicity
IV Infusion Toxicity
- Slow infusion rate is critical (≤50 mg/min in adults; ≤1 mg/kg/min in elderly/cardiac patients)
- Hypotension: Stop or slow infusion → isotonic crystalloid; usually responds promptly
- Bradycardia/heart block: Atropine; temporary cardiac pacing for symptomatic bradyrhythmias
- Fosphenytoin preferred over IV phenytoin for parenteral use (lower CV risk, no propylene glycol)
Hypersensitivity
- Discontinue phenytoin immediately
- Manage per the severity (corticosteroids, supportive care for SJS)
Disposition
| Scenario | Disposition |
|---|---|
| Serious complications (seizures, coma, significant AMS/ataxia) | Admit |
| Mild symptoms, declining levels, clinically improving | Observe in ED; discharge once levels declining and clinically well |
| Chronic intoxication — minimal signs, adequate home care, level declining | May discharge after 6–8 hours since last dose |
| Intentional overdose | Psychiatric evaluation before discharge |
Key principle: Phenytoin therapy should be stopped in all cases of toxicity. If toxicity resolves, levels may be reassessed in 2–3 days to guide resumption.
— Tintinalli's Emergency Medicine: A Comprehensive Study Guide, Chapter 197 (Anticonvulsants), pp. 1325–1326
This is a shared conversation. Sign in to Orris to start your own chat.